Retrospective analysis of 140 cases of medullary thyroid carcinoma followed‑up in a single institution

Simões‑Pereira,Joana; Bugalho,Maria João; Limbert,Edward; Leite,Valeriano

doi:10.3892/ol.2016.4482

Retrospective analysis of 140 cases of medullary thyroid carcinoma followed‑up in a single institution

Authors:
- Joana Simões‑Pereira
- Maria João Bugalho
- Edward Limbert
- Valeriano Leite
View Affiliations

Affiliations: Department of Endocrinology, Portuguese Institute of Oncology Francisco Gentil, Lisbon 1099‑023, Portugal
Published online on: April 20, 2016 https://doi.org/10.3892/ol.2016.4482
Pages: 3870-3874

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Familial cases of medullary thyroid carcinoma (MTC) may be diagnosed by genetic screening, while in sporadic tumors the diagnosis relies mainly on fine‑needle aspiration cytology. The aim of the present study was to determine the demographic, clinical and pathological characteristics of MTC patients followed‑up at the Portuguese Institute of Oncology Francisco Gentil (Lisbon, Portugal). For that purpose, a retrospective analysis of 140 MTC patients diagnosed between 1990 and 2010 was performed. The results indicated that patients with hereditary MTC (11.4%) were significantly younger than patients with sporadic MTC. Of the latter, 34.3% had no clinical suspicion of MTC prior to surgery. The sensitivity of cytology and calcitonin (CT) assay in diagnosing MTC were 51.3 and 98.7%, respectively. All familial index cases and 69.0% of sporadic cases presented with advanced stage disease at the time of diagnosis, while 73.0% of familial MTC detected by genetic/pentagastrin screening were diagnosed at the early stage of the disease. Biochemical cure (BC) was achieved in 39.7% of patients and, of these, only 6.5% relapsed. The 5 and 10‑year survival rates were 79.3 and 73.6%, respectively. Age >45 years (P=0.026), advanced stage at diagnosis (P<0.001) and absence of BC (P<0.001) were predictors of a worse prognosis on univariate analysis. However, when the patients detected by genetic/pentagastrin screening were excluded from the analysis, age was no longer a prognostic factor, although disease stage remained a significant prognostic factor. On multivariate analysis, BC was the only factor with a significant impact on prognosis (P=0.031). In addition, the present study confirmed that the majority of patients were diagnosed at advanced stages, and CT determination was observed to be more sensitive than cytology to diagnose MTC. Patients at early stages were more prone to achieve BC, which was a favorable prognostic factor. To the best of our knowledge, the present study reports for the first time that age at diagnosis is not a predictor of survival for patients with MTC when cases diagnosed by genetic/pentagastrin screening (who are usually young patients at the initial stages of the disease), are excluded from the analysis.

View Figures

View References

1	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
2	Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M and Wells SA Jr: American Thyroid Association Guidelines Task Force: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid. 19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
3	Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A and Pacini F: Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 89:163–168. 2004. View Article : Google Scholar : PubMed/NCBI
4	Evans DB, Fleming JB, Lee JE, Cote G and Gagel RF: The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 16:50–63. 1999. View Article : Google Scholar : PubMed/NCBI
5	Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF and Evans DB: Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 230:697–707. 1999. View Article : Google Scholar : PubMed/NCBI
6	Kebebew E, Ituarte PH, Siperstein AE, Duh QY and Clark OH: Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 88:1139–1148. 2000. View Article : Google Scholar : PubMed/NCBI
7	Leboulleux S, Baudin E, Travagli JP and Schlumberger M: Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 61:299–310. 2004. View Article : Google Scholar : PubMed/NCBI
8	Greene FL, Page DL, Fleming ID, Fritz A and Balch DM: AJCC Cancer Staging Manual (6th). Springer Verlag. Chicago: 2003.
9	Bugalho MJ, Domingues R, Santos JR, Catarino AL and Sobrinho L: Mutation analysis of the RET proto-oncogene and early thyroidectomy: Results of a Portuguese cancer centre. Surgery. 141:90–95. 2007. View Article : Google Scholar : PubMed/NCBI
10	Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ and Leite V: Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 100:1777–1783. 2009. View Article : Google Scholar : PubMed/NCBI
11	Moura MM, Cavaco BM, Pinto AE and Leite V: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 96:E863–E868. 2011. View Article : Google Scholar : PubMed/NCBI
12	Marsh DJ, Learoyd DL and Robinson BG: Medullary thyroid carcinoma: Recent advances and management update. Thyroid. 5:407–424. 1995. View Article : Google Scholar : PubMed/NCBI
13	Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L and Vitti P: AACE/AME/ETA Task Force on Thyroid Nodules: American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive summary of recommendations. J Endocrinol Invest. 33(Suppl 5): S51–S56. 2010.
14	Bugalho MJ, Santos JR and Sobrinho L: Preoperative diagnosis of medullary thyroid carcinoma: Fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 91:56–60. 2005. View Article : Google Scholar : PubMed/NCBI
15	Papaparaskeva K, Nagel H and Droese M: Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 22:351–358. 2000. View Article : Google Scholar : PubMed/NCBI
16	Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Röher HD and Knoefel WT: Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: A single institution's experience over 20 years. Ann Surg. 246:815–821. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wells SA Jr and Franz C: Medullary carcinoma of the thyroid gland. World J Surg. 24:952–956. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kameyama K and Takami H: Medullary thyroid carcinoma: Nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. Endocr J. 51:453–456. 2004. View Article : Google Scholar : PubMed/NCBI
19	Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, et al: Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 48:265–273. 1998. View Article : Google Scholar : PubMed/NCBI
20	Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I and Lapidot M: Medullary thyroid cancer: A retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid. 17:549–556. 2007. View Article : Google Scholar : PubMed/NCBI
21	Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, et al: Groupe Français des Tumeurs Endocrines: Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: A multicenter study of the Groupe Français d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab. 96:E509–E518. 2011. View Article : Google Scholar : PubMed/NCBI
22	Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Höppner W and Raue F: Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: Impact of individual RET genotype. Eur J Endocrinol. 155:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G and Colombo L: Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 77:1556–1565. 1996. View Article : Google Scholar : PubMed/NCBI